Macitentan in daily clinical practice: A single centre, 1-year experience
The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's exper...
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
Taylor & Francis
2018-05-01
|
| シリーズ: | Pulmonology |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2173511517301495 |